| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 809,991 | |||
| General and administrative | 1,450,269 | |||
| Total operating expenses | 2,260,260 | |||
| Loss from operations | -2,260,260 | |||
| Interest expense | 17,439 | |||
| Interest income | 109,616 | |||
| Grant income | 9,825 | |||
| Other | -96 | |||
| Other income, net | 101,906 | |||
| Net loss | -2,158,354 | |||
| Net loss per share, basic | -0.05 | |||
| Net loss per share, diluted | -0.05 | |||
| Weighted average common shares outstanding, basic | 41,084,731 | |||
| Weighted average common shares outstanding, diluted | 41,084,731 | |||
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)